Related references
Note: Only part of the references are listed.Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
Shuichi Hironaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
R. Michael Baldwin et al.
CLINICAL CANCER RESEARCH (2012)
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study
Chunqiao Tian et al.
GYNECOLOGIC ONCOLOGY (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy
Kohei Shitara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials
Donald A. Berry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
S. Leskelae et al.
PHARMACOGENOMICS JOURNAL (2011)
Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel
K. Shitara et al.
ANNALS OF ONCOLOGY (2010)
Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
Volker Moebus et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03
Y. Kishida et al.
BRITISH JOURNAL OF CANCER (2009)
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
Kohei Shitara et al.
EUROPEAN JOURNAL OF CANCER (2009)
Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Is there a role for second-line chemotherapy in advanced gastric cancer?
Robert Wesolowski et al.
LANCET ONCOLOGY (2009)
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
V. Catalano et al.
BRITISH JOURNAL OF CANCER (2008)
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy
A. G. Pallis et al.
LUNG CANCER (2008)
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-I in advanced gastric carcinoma
T. Yamanaka et al.
BRITISH JOURNAL OF CANCER (2007)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer
Vernon Harvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: An analysis from the German Hodgkin Study Group
B Klimm et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials
M Di Maio et al.
LANCET ONCOLOGY (2005)
How to calculate the dose of chemotherapy
H Gurney
BRITISH JOURNAL OF CANCER (2002)
Share Paper
